HRP20201141T1 - Nutritivna kompozicija za primjenu u terapiji pacijenata sa sarkopenijom i/ili slabošću ili pacijenta sa presarkopenijom i/ili pred-slabošću - Google Patents

Nutritivna kompozicija za primjenu u terapiji pacijenata sa sarkopenijom i/ili slabošću ili pacijenta sa presarkopenijom i/ili pred-slabošću Download PDF

Info

Publication number
HRP20201141T1
HRP20201141T1 HRP20201141TT HRP20201141T HRP20201141T1 HR P20201141 T1 HRP20201141 T1 HR P20201141T1 HR P20201141T T HRP20201141T T HR P20201141TT HR P20201141 T HRP20201141 T HR P20201141T HR P20201141 T1 HRP20201141 T1 HR P20201141T1
Authority
HR
Croatia
Prior art keywords
patients
vitamin
sarcopenia
weakness
nutritional composition
Prior art date
Application number
HRP20201141TT
Other languages
English (en)
Inventor
Edmundo BRITO-DE-LA-FUENTE
Ericka PESTANA
Stephanie REICHART
Maria Fernanda MARTINEZ-BOCK
José Maria MAINOU-SIERRA
Sarah ASHLEY-MAGUIRE
Original Assignee
Fresenius Kabi Deutschland Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fresenius Kabi Deutschland Gmbh filed Critical Fresenius Kabi Deutschland Gmbh
Publication of HRP20201141T1 publication Critical patent/HRP20201141T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A23L33/155—Vitamins A or D
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Inorganic Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Claims (16)

1. PUFA, vitamin E, vitamin D i aminokiseline glicin, arginin i triptofan vezane za proteine kao aktivni sastojci za primjenu u terapiji pacijenata sa sarkopenijom i/ili slabošću ili pacijenata sa presarkopenijom ili pred-slabošću, pri čemu efikasna količina navedenih aktivnih sastojaka se administrira u obliku nutritivne kompozicije koja sadrži a) lipidnu komponentu koja osigurava 40-50 EN% zasnovano na ukupnoj energiji nutritivne kompozicije, pri čemu 12-16 EN% zasnovano na ukupnoj energiji nutritivne kompozicije osigurava PUFA, b) 4.0-8.0 mg/100mL alfa-TE vitamina E, c) 5.0-12.0 µg/100mL vitamina D, d) 2.5-4.5 g/100mL glicina, e) 0.5-1.5 g/100mL arginina, i f) najmanje 0.02 g/100mL triptofana.
2. PUFA, vitamin E, vitamin D i aminokiseline glicin, arginin i triptofan vezane za proteine kao aktivni sastojci za primjenu u terapiji pacijenata sa sarkopenijom i/ili slabošću ili pacijenata sa presarkopenijom ili pred-slabošću prema prethodnom patentnom zahtjevu, pri čemu nutritivna kompozicija ima kalorijsku gustoću od najmanje 2.0 kcal/mL.
3. PUFA, vitamin E, vitamin D i aminokiseline glicin, arginin i triptofan vezane za proteine kao aktivni sastojci za primjenu u terapiji pacijenata sa sarkopenijom i/ili slabošću ili pacijenata sa presarkopenijom ili pred-slabošću prema bilo kojem od prethodnih patentnih zahtjeva, pri čemu nutritivna kompozicija sadrži najmanje 14 g proteina po 100 mL nutritivne kompozicije.
4. PUFA, vitamin E, vitamin D i aminokiseline glicin, arginin i triptofan vezane za proteine kao aktivni sastojci za primjenu u terapiji pacijenata sa sarkopenijom i/ili slabošću ili pacijenata sa presarkopenijom ili pred-slabošću prema bilo kojem od prethodnih patentnih zahtjeva, pri čemu proteinska komponenta osigurava najmanje 15 EN% zasnovano na ukupnoj energiji nutritivne kompozicije.
5. PUFA, vitamin E, vitamin D i aminokiseline glicin, arginin i triptofan vezane za proteine kao aktivni sastojci za primjenu u terapiji pacijenata sa sarkopenijom i/ili slabošću ili pacijenata sa presarkopenijom ili pred-slabošću prema bilo kojem od prethodnih patentnih zahtjeva, pri čemu nutritivna kompozicija dalje sadrži ugljikohidratnu komponentu koja osigurava najmanje 20 EN% zasnovano na ukupnoj energiji nutritivne kompozicije.
6. PUFA, vitamin E, vitamin D i aminokiseline glicin, arginin i triptofan vezane za proteine kao aktivni sastojci za primjenu u terapiji pacijenata sa sarkopenijom i/ili slabošću ili pacijenata sa presarkopenijom ili pred-slabošću prema bilo kojem od prethodnih patentnih zahtjeva, pri čemu proteinska komponenta osigurava 15-25 EN% zasnovano na ukupnoj energiji nutritivne kompozicije, i pri čemu nutritivna kompozicija dalje sadrži ugljikohidratnu komponentu koja osigurava 30-40 EN% zasnovano na ukupnoj energiji nutritivne kompozicije.
7. PUFA, vitamin E, vitamin D i aminokiseline glicin, arginin i triptofan vezane za proteine kao aktivni sastojci za primjenu u terapiji pacijenata sa sarkopenijom i/ili slabošću ili pacijenata sa presarkopenijom ili pred-slabošću prema bilo kojem od prethodnih patentnih zahtjeva, pri čemu 24-32 EN% zasnovano na ukupnoj energiji nutritivne kompozicije osigurava MUFA, i 1-5 EN% zasnovano na ukupnoj energiji nutritivne kompozicije osigurava SFA.
8. PUFA, vitamin E, vitamin D i aminokiseline glicin, arginin i triptofan vezane za proteine kao aktivni sastojci za primjenu u terapiji pacijenata sa sarkopenijom i/ili slabošću ili pacijenata sa presarkopenijom ili pred-slabošću prema bilo kojem od prethodnih patentnih zahtjeva, pri čemu proteinska komponenta sadrži hidrolizirani kolagen.
9. PUFA, vitamin E, vitamin D i aminokiseline glicin, arginin i triptofan vezane za proteine kao aktivni sastojci za primjenu u terapiji pacijenata sa sarkopenijom i/ili slabošću ili pacijenata sa presarkopenijom ili pred-slabošću prema bilo kojem od prethodnih patentnih zahtjeva, pri čemu proteinska komponenta sadrži izvor proteina izabran od biljnih proteina, životinjskih proteina osim kolagena i njihovih smjesa.
10. PUFA, vitamin E, vitamin D i aminokiseline glicin, arginin i triptofan vezane za proteine kao aktivni sastojci za primjenu u terapiji pacijenata sa sarkopenijom i/ili slabošću ili pacijenata sa presarkopenijom ili pred-slabošću prema bilo kojem od prethodnih patentnih zahtjeva, pri čemu nutritivna kompozicija dalje sadrži 50-300 mg/100mL kalcija.
11. PUFA, vitamin E, vitamin D i aminokiseline glicin, arginin i triptofan vezane za proteine kao aktivni sastojci za primjenu u terapiji pacijenata sa sarkopenijom i/ili slabošću ili pacijenata sa presarkopenijom ili pred-slabošću prema bilo kojem od prethodnih patentnih zahtjeva, pri čemu je nutritivna kompozicija nutritivno kompletna.
12. PUFA, vitamin E, vitamin D i aminokiseline glicin, arginin i triptofan vezane za proteine kao aktivni sastojci za primjenu u terapiji pacijenata sa sarkopenijom i/ili slabošću ili pacijenata sa presarkopenijom ili pred-slabošću prema bilo kojem od prethodnih patentnih zahtjeva, pri čemu su pacijenti stariji pacijenti (starosti ≥ 65) koji imaju BMI < 22 kg/m2.
13. PUFA, vitamin E, vitamin D i aminokiseline glicin, arginin i triptofan vezane za proteine kao aktivni sastojci za primjenu u terapiji pacijenata sa sarkopenijom i/ili slabošću ili pacijenata sa presarkopenijom ili pred-slabošću prema bilo kojem od prethodnih patentnih zahtjeva, pri čemu su pacijenti stariji pacijenti (starosti ≥ 65) koji imaju FFMI < 16 kg/m2, ako su žene, i imaju FFMI < 18 kg/m2, ako su muškarci.
14. PUFA, vitamin E, vitamin D i aminokiseline glicin, arginin i triptofan vezane za proteine kao aktivni sastojci za primjenu u terapiji pacijenata sa sarkopenijom i/ili slabošću ili pacijenata sa presarkopenijom ili pred-slabošću prema bilo kojem od prethodnih patentnih zahtjeva, pri čemu je nutritivna kompozicija osigurana u doznoj jedinici od 100-200 mL ili u doznoj jedinici koja osigurava 300-500kcal ili u doznoj jedinici koja osigurava 15-30g proteina.
15. PUFA, vitamin E, vitamin D i aminokiseline glicin, arginin i triptofan vezane za proteine kao aktivni sastojci za primjenu u terapiji pacijenata sa sarkopenijom i/ili slabošću ili pacijenata sa presarkopenijom ili pred-slabošću prema bilo kojem od prethodnih patentnih zahtjeva, pri čemu se nutritivna kompozicija administrira u dnevnoj dozi od 1500-2500kcal ili u dnevnoj dozi od 300-900kcal ili u dnevnoj dozi od 75-125g proteina ili u dnevnoj dozi od 15-45g proteina.
16. Nutritivna kompozicija koja sadrži a) lipidnu komponentu koja osigurava 40-50 EN% zasnovano na ukupnoj energiji nutritivne kompozicije, pri čemu 12-16 EN% zasnovano na ukupnoj energiji nutritivne kompozicije osigurava PUFA, b) 4.0-8.0 mg/100mL alfa-TE vitamina E, c) 5.0-12.0 µg/100mL vitamina D, d) 2.5-4.5 g/100mL glicina, e) 0.5-1.5 g/100mL arginina, i f) najmanje 0.02 g/100mL triptofana.
HRP20201141TT 2016-11-16 2020-07-21 Nutritivna kompozicija za primjenu u terapiji pacijenata sa sarkopenijom i/ili slabošću ili pacijenta sa presarkopenijom i/ili pred-slabošću HRP20201141T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16199106 2016-11-16
PCT/EP2017/079392 WO2018091564A1 (en) 2016-11-16 2017-11-16 Nutritional composition for use in therapy of patients with sarcopenia and/or frailty or pre-sarcopenic and/or pre-frail patients
EP17798213.9A EP3541206B1 (en) 2016-11-16 2017-11-16 Nutritional composition for use in therapy of patients with sarcopenia and/or frailty or pre-sarcopenic and/or pre-frail patients

Publications (1)

Publication Number Publication Date
HRP20201141T1 true HRP20201141T1 (hr) 2020-10-30

Family

ID=57345764

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20201141TT HRP20201141T1 (hr) 2016-11-16 2020-07-21 Nutritivna kompozicija za primjenu u terapiji pacijenata sa sarkopenijom i/ili slabošću ili pacijenta sa presarkopenijom i/ili pred-slabošću

Country Status (8)

Country Link
US (1) US11612578B2 (hr)
EP (2) EP3711493A1 (hr)
CN (1) CN109982585B (hr)
AU (1) AU2017361804B2 (hr)
BR (1) BR112019009757B1 (hr)
HR (1) HRP20201141T1 (hr)
WO (1) WO2018091564A1 (hr)
ZA (1) ZA201902873B (hr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108783467B (zh) * 2018-06-04 2021-08-06 中食月太(北京)健康科技有限公司 改善骨质疏松和增加骨密度的组合物及其制备方法
JP2022534471A (ja) * 2019-05-31 2022-08-01 ソシエテ・デ・プロデュイ・ネスレ・エス・アー 動物における健康効果を提供するためのｍｃｔベースの栄養ブレンド
AU2020287907A1 (en) * 2019-06-07 2021-11-04 Société des Produits Nestlé S.A. Compositions and methods using one or more autophagy-inducing amino acids to potentiate musculoskeletal effect of one or more anabolic amino acids
CN114072147A (zh) * 2019-07-05 2022-02-18 雀巢产品有限公司 使用葫芦巴碱和高蛋白质来预防或治疗骨骼肌病症或障碍的组合物和方法
US20220241259A1 (en) * 2019-07-05 2022-08-04 Societe Des Produits Nestle S.A. Compositions and methods using trigonelline and vitamins for preventing or treating conditions or disorders in skeletal muscle
EP4125442A1 (en) * 2020-04-01 2023-02-08 Société des Produits Nestlé S.A. Compositions containing amino acids and methods of using such compositions for treating sarcopenia

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4025650A (en) * 1975-11-24 1977-05-24 Control Drug, Inc. Method and composition for preventing nutritional deficiency
JP2540204B2 (ja) 1988-08-18 1996-10-02 ナシヨナル・スターチ・アンド・ケミカル・コーポレイション 保存安定性を有する化工でんぷん乳化剤
US5221668A (en) * 1992-02-26 1993-06-22 Abbott Laboratories Nutritional product for trauma and surgery patients
US20040087490A1 (en) * 2002-09-20 2004-05-06 Troup John P. Nutritional compositions
RU2388478C2 (ru) * 2003-10-24 2010-05-10 Н.В. Нютрисиа Иммуномодулирующие олигосахариды
WO2008115563A1 (en) * 2007-03-19 2008-09-25 University Of Florida Research Foundation, Inc. Liquid nutrient composition for improving performance
CA2768471A1 (en) * 2009-07-20 2011-01-27 Nestec S.A. Methods of attenuating the loss of functional status
WO2011078654A1 (en) 2009-12-24 2011-06-30 N.V. Nutricia Low-caloric high-protein nutritional composition for the stimulation of muscle protein synthesis
US8603555B2 (en) * 2010-04-13 2013-12-10 Mark A. Innocenzi Methods for quantifying the complete nutritional value of a standard equivalent unit of the nutritional value of one serving of fruits and vegetables (SFV)and for fortifying a base food to contain same for human consumption
WO2012005568A1 (en) 2010-07-07 2012-01-12 N.V. Nutricia Nutritional composition for the stimulation of muscle protein synthesis
WO2012024611A1 (en) * 2010-08-20 2012-02-23 Natural Alternatives International, Inc. Methods of treating sarcopenia and frailty
DE102010060564A1 (de) * 2010-11-15 2012-05-16 Gelita Ag Verwendung von Kollagenhydrolysat zur Verbesserung der Gesundheit der menschlichen Haut, Haare und/oder Nägel
WO2012091542A1 (en) * 2010-12-28 2012-07-05 N.V. Nutricia Combination of components for the prevention and treatment of frailty
AU2012244748B2 (en) * 2011-04-18 2016-07-14 Nestec S.A. Nutritional compositions comprising alpha-hydroxyisocaproic acid
CN103783532B (zh) * 2012-10-29 2016-06-08 杭州纽曲星生物科技有限公司 一种抗老年性肌肉衰减的复合蛋白质粉及其制备方法
US9961932B2 (en) * 2013-06-10 2018-05-08 N.V. Nutricia Muscle preservation in overweight or obese adult during weight loss program

Also Published As

Publication number Publication date
BR112019009757A2 (pt) 2019-08-13
AU2017361804A1 (en) 2019-05-23
WO2018091564A1 (en) 2018-05-24
CN109982585B (zh) 2024-03-15
ZA201902873B (en) 2020-10-28
US20200061013A1 (en) 2020-02-27
CN109982585A (zh) 2019-07-05
BR112019009757B1 (pt) 2022-12-20
AU2017361804B2 (en) 2021-09-09
EP3541206B1 (en) 2020-05-13
EP3541206A1 (en) 2019-09-25
US11612578B2 (en) 2023-03-28
EP3711493A1 (en) 2020-09-23

Similar Documents

Publication Publication Date Title
HRP20201141T1 (hr) Nutritivna kompozicija za primjenu u terapiji pacijenata sa sarkopenijom i/ili slabošću ili pacijenta sa presarkopenijom i/ili pred-slabošću
Chalamaiah et al. Chemical composition and immunomodulatory effects of enzymatic protein hydrolysates from common carp (Cyprinus carpio) egg
Achamrah et al. Glutamine and the regulation of intestinal permeability: from bench to bedside
ES2702752T3 (es) Formulaciones de alimentación con sonda y métodos de utilización de las mismas
DK1898724T3 (da) Spædbarnsernæring med hydrolyserede proteiner
JP2015147773A5 (hr)
CY1108033T1 (el) Βελτιωμενη παιδιατρικη συνθεση και μεθοδοι για την παροχη τροφης και τη βελτιωση της ανεκτικοτητος
BRPI0713377A2 (pt) formulação nutritiva, e, uso de uma formulação
EP4218819A3 (en) Combination therapy based on pd-1 signal inhibitors
ES2189427T3 (es) Productos nutricional para una persona que tiene fallo renal.
HRP20140238T1 (hr) Hrana za dojilje
MX2018014083A (es) Composiciones nutritivas para la proteccion cardiaca en animales de compañia.
AR110060A1 (es) Composiciones nutricionales que proporcionan el manejo dietético de cólicos
BR112012021053A2 (pt) Formulacoes e metodos para distribuicao de nutrientes
ES2162586B1 (es) Composicion que comprende aceites ozonizados y/o otros productos naturales y/o sinteticos ozonizados, y su empleo en composiciones farmaceuticas, cosmeticas, dieteticas o de suplementos alimentarios, en los campos humano y veterinario
NO20053788D0 (no) Anvendelse av lupin-konglutin for behandlingen av type II diabetes.
ES2195902T3 (es) Composicion que comprende esfingomielinasa alcalina para uso como preparacion dietetica, complemento alimenticio o producto farmaceutico.
McDougall et al. Plant-based diets are not nutritionally deficient
BR0215904A (pt) Métodos e composições para prover glutamina
ES2179485T3 (es) Composicion solida adecuada para la administracion oral, que contiene fumarato de l-carnitina magnesio, o fumarato de alcanoil-l-carnitina magnesio.
ES2196053T3 (es) Procedimiento para el tratamiento de trastornos del cuerpo humano o animal mediante la administracion de aminoacidos.
Bufano Keeping eggs safe from farm to table
RU2015133023A (ru) Активация адипонектина с использованием гидролизата казеина
ATE217494T1 (de) Orale darreichungsform
Liu et al. The immunomodulatory activity of jacaric acid, a conjugated linolenic acid isomer, on murine peritoneal macrophages